| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Health Foundation, Valhalla, New York 10595
The tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), selectively induces lung tumors in F344 rats. NNK is metabolically activated to intermediates that methylate and pyridyloxobutylate DNA. To explore the importance of pyridyloxobutyl DNA adducts in NNK-induced rat lung tumorigenesis, the first study in this report examined levels of these adducts in whole lung and pulmonary cells of F344 rats treated with different doses of NNK (0.3, 1.0, 10.0, and 50 mg/kg; 3 x weekly for 2 weeks). Pyridyloxobutyl DNA adducts were highest in Clara cells compared to alveolar Type II cells, alveolar macrophages, and small cells, suggesting that enzymes involved in the formation of the pyridyloxobutylating species are concentrated in Clara cells. When we compared lung tumor incidence at the different doses of NNK (S. A. Belinsky et al., Cancer Res., 50: 37723780, 1990) versus pyridyloxobutyl DNA adducts in Type II cells, we observed a significant correlation. Because NNK-induced lung tumors arise from the Type II cells, this suggests an important role for pyridyloxobutyl DNA adducts. In the second study presented in this report, we examined the effect of dietary phenethyl isothiocyanate (PEITC), an inhibitor of lung tumor induction in F344 rats by NNK, on O6-methyldeoxyguanosine (O6-mG) and pyridyloxobutyl DNA adducts in whole lung and lung cells of F344 rats treated with NNK. F344 rats were fed control or PEITC-containing diets (3 µmol/g diet) before and throughout NNK treatment (1.76 mg/kg, three times weekly for 4, 8, 12, 16, or 20 weeks). PEITC inhibited formation of pyridyloxobutyl DNA adducts in whole lung and all lung cells except macrophages. There was also inhibition of O6-mG, but it varied with cell type and length of NNK treatment. Overall, PEITC treatment decreased pyridyloxobutyl DNA adducts by 57% in Clara cells, 51% in Type II cells, 40% in small cells, and 44% in whole lung. PEITC treatment decreased O6-mG levels by 52% in Clara cells, 19% in Type II cells and small cells, and 36% in whole lung. These results support the hypothesis that PEITC inhibition of NNK-induced lung tumors is a result of decreased metabolic activation and DNA binding of NNK. The 50% reduction of pyridyloxobutyl DNA adducts in Type II cells agreed well with the 50% reduction of NNK-induced lung tumors by PEITC. Because NNK-induced tumors arise from Type II cells, these results suggest an important role for pyridyloxobutyl DNA adducts in NNK-induced rat lung tumorigenesis.
1 This study was supported by Grant CA-46535 from the National Cancer Institute.
2 Present address: Alteon, Inc., Ramsey, NJ 07446.
3 To whom requests for reprints should be addressed, at University of Minnesota Cancer Center, Box 806-UMHC, 420 Delaware St. SE, Minneapolis, MN 55455.
Received 8/12/96. Accepted 11/14/96.
This article has been cited by other articles:
![]() |
Y. Weng, C. Fang, R. J. Turesky, M. Behr, L. S. Kaminsky, and X. Ding Determination of the Role of Target Tissue Metabolism in Lung Carcinogenesis Using Conditional Cytochrome P450 Reductase-Null Mice Cancer Res., August 15, 2007; 67(16): 7825 - 7832. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-Y. Choi, G. Chowdhury, H. Zang, K. C. Angel, C. C. Vu, L. A. Peterson, and F. P. Guengerich Translesion Synthesis across O6-Alkylguanine DNA Adducts by Recombinant Human DNA Polymerases J. Biol. Chem., December 15, 2006; 281(50): 38244 - 38256. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Mijal, S. Kanugula, C. C. Vu, Q. Fang, A. E. Pegg, and L. A. Peterson DNA Sequence Context Affects Repair of the Tobacco-Specific Adduct O6-[4-Oxo-4-(3-pyridyl)butyl]guanine by Human O6-Alkylguanine-DNA Alkyltransferases. Cancer Res., May 1, 2006; 66(9): 4968 - 4974. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Boysen, P. M.J. Kenney, P. Upadhyaya, M. Wang, and S. S. Hecht Effects of benzyl isothiocyanate and 2-phenethyl isothiocyanate on benzo[a]pyrene and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone metabolism in F-344 rats Carcinogenesis, March 1, 2003; 24(3): 517 - 525. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. R.K. Sticha, P. M.J. Kenney, G. Boysen, H. Liang, X. Su, M. Wang, P. Upadhyaya, and S. S. Hecht Effects of benzyl isothiocyanate and phenethyl isothiocyanate on DNA adduct formation by a mixture of benzo[a]pyrene and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in A/J mouse lung Carcinogenesis, September 1, 2002; 23(9): 1433 - 1439. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Peterson, N. M. Thomson, D. L. Crankshaw, E. E. Donaldson, and P. J. Kenney Interactions between Methylating and Pyridyloxobutylating Agents in A/J Mouse Lungs: Implications for 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced Lung Tumorigenesis Cancer Res., August 1, 2001; 61(15): 5757 - 5763. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Hecht, S. G. Carmella, and S. E. Murphy Effects of Watercress Consumption on Urinary Metabolites of Nicotine in Smokers Cancer Epidemiol. Biomarkers Prev., October 1, 1999; 8(10): 907 - 913. [Abstract] [Full Text] |
||||
![]() |
G. B.J. Smith, A. Castonguay, P. J. Donnelly, K. R. Reid, D. Petsikas, and T. E. Massey Biotransformation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in freshly isolated human lung cells Carcinogenesis, September 1, 1999; 20(9): 1809 - 1818. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. M. Schuller, P. K. Tithof, M. Williams, and H. Plummer III The Tobacco-specific Carcinogen 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone Is a {beta}-Adrenergic Agonist and Stimulates DNA Synthesis in Lung Adenocarcinoma via {beta}-Adrenergic Receptor-mediated Release of Arachidonic Acid Cancer Res., September 1, 1999; 59(18): 4510 - 4515. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Liu, X. Qin, and S. L. Gerson Reduced lung tumorigenesis in human methylguanine DNA—methyltransferase transgenic mice achieved by expression of transgene within the target cell Carcinogenesis, February 1, 1999; 20(2): 279 - 284. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. C. Conaway, D. Jiao, T. Kohri, L. Liebes, and F.-L. Chung Disposition and Pharmacokinetics of Phenethyl Isothiocyanate and 6-Phenylhexyl Isothiocyanate in F344 Rats Drug Metab. Dispos., January 1, 1999; 27(1): 13 - 20. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |